Viridian Therapeutics (VRDN) AI Stock Analysis

• Market Cap: $1.18B
• Dividend Yield: N/A
• Average Volume (3M): 835.76K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.87
• Revenue Growth: -3.82%
• EPS Growth: 29.10%
• Country: US
• Employees: 143
• Sector: Healthcare
• Sector Strength: 72
• Industry: Biotechnology
• EPS (TTM): -3.77
• Shares Outstanding: 81,484,950
• 10 Day Avg. Volume: 752,809
• 30 Day Avg. Volume: 835,756
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 4117.42
• Price to Cash Flow (P/CF): -4.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $41.11
• Price Target Upside: 204.97% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10

Viridian Therapeutics' stock score reflects significant financial challenges and poor technical indicators, offset by positive corporate developments. The absence of revenue and negative cash flows highlight major risks, while the promising clinical trial results offer potential upside. Overall, the stock faces substantial hurdles but has opportunities if it can capitalize on its recent clinical success.

Positive Factors

Clinical Trials

Positive topline results from the Phase 3 THRIVE-2 study of lead asset veligrotug in chronic thyroid eye disease, demonstrating differentiated efficacy data that build on the successful Phase 3 THRIVE study.

Financial Stability

Viridian’s cash and short-term investments stood at $717.6M, which is expected to provide sufficient operating runway into the second half of 2027.

Market Position

Given that Tepezza is now a ~$1.9B product in the US, veligrotug is positioned to rapidly capture significant share in the TED market.

Negative Factors

Market Competition

Unlike the TED market, where Viridian has been able to demonstrate differentiated efficacy, the FcRn market is considerably more crowded with a number of large competitors.

Viridian Therapeutics Business Overview & Revenue Model

Company Description

Viridian Therapeutics, Inc. (VRDN) is a biotechnology company focused on developing innovative therapies for patients with serious diseases. The company primarily operates in the biopharmaceutical sector and is dedicated to advancing treatments for rare and underserved conditions, with a particular emphasis on endocrine and ophthalmic diseases. Viridian leverages its expertise in antibody technology to create novel therapeutic candidates aimed at improving patient outcomes and quality of life.

How the Company Makes Money

Viridian Therapeutics makes money through the development and commercialization of its proprietary drug candidates. The company's revenue model typically involves the sale of pharmaceutical products upon receiving regulatory approval and successfully launching them to the market. Additionally, Viridian may engage in strategic collaborations and partnerships with other pharmaceutical companies to co-develop therapies, which can provide milestone payments, royalties, and licensing fees as additional revenue streams. These partnerships can also enhance the company's research and development capabilities while expanding its market reach for the commercialized therapies.

Viridian Therapeutics Financial Statement Overview

Summary

Viridian Therapeutics faces significant financial challenges with no revenue generation in 2024, consistent operational inefficiencies, and negative free cash flow. Despite a strong cash position and low leverage, the sustainability risks due to ongoing losses and cash burn rate are concerning.

Income Statement

Viridian Therapeutics has struggled with revenue generation, evident from the decrease in total revenue from $4.46M in 2019 to zero in 2024, indicating significant challenges in market traction or product development. Consistently negative net income and EBIT highlight ongoing operational inefficiencies. The company also experienced declining gross and net profit margins over the years, reflecting persistent unprofitability.

Balance Sheet

The balance sheet reveals a strong cash position with cash and cash equivalents growing to $717.6M by 2024, but the absence of revenue poses a risk to long-term sustainability. The company's debt-to-equity ratio is favorable due to minimal debt, suggesting low leverage. However, a consistent decline in equity ratio from 52% in 2019 to 90% in 2024 reflects potential over-reliance on equity financing.

Cash Flow

Operating cash flow has been consistently negative, indicating that the company is not generating sufficient cash from its core operations. While there is a notable increase in financing cash flow, reflecting successful fundraising efforts, free cash flow remains negative, pointing to potential cash burn issues. The absence of revenue growth and high cash burn rate are concerning for future liquidity.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
302.00K	314.00K	1.77M	2.96M	1.05M
	Gross Profit
302.00K	-1.01M	1.02M	2.34M	-27.25M
	EBIT
-299.04M	-254.45M	-134.30M	-79.73M	-110.38M
	EBITDA
-266.36M	-234.56M	-128.63M	-78.79M	-109.67M
	Net Income Common Stockholders
-269.95M	-237.73M	-125.44M	-79.42M	-110.98M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
717.58M	477.37M	424.55M	196.97M	127.64M
	Total Assets
742.40M	490.42M	435.09M	203.71M	131.25M
	Total Debt
21.09M	21.05M	5.26M	520.00K	455.00K
	Net Debt
-78.50M	-81.78M	-150.32M	-41.78M	-45.44M
	Total Liabilities
70.76M	48.40M	40.03M	15.99M	11.22M
	Stockholders Equity
671.64M	442.02M	395.06M	187.72M	120.04M
Cash Flow		Free Cash Flow
-232.83M	-185.07M	-94.64M	-54.92M	-29.82M
	Operating Cash Flow
-232.32M	-184.17M	-93.84M	-54.58M	-29.78M
	Investing Cash Flow
-228.65M	-94.25M	-115.13M	-74.29M	-50.48M
	Financing Cash Flow
457.74M	225.67M	322.24M	125.28M	101.31M

Viridian Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 13.48
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VRDN, the sentiment is Negative. The current price of 13.48 is below the 20-day moving average (MA) of 15.33, below the 50-day MA of 16.69, and below the 200-day MA of 18.06, indicating a bearish trend. The MACD of -0.66 indicates Positive momentum. The RSI at 32.51 is Neutral, neither overbought nor oversold. The STOCH value of 20.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VRDN.

Viridian Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
REGN	78 Outperform	$69.68B	16.63	15.95%	0.14%	8.27%	10.35%
BMRN	78 Outperform	$13.63B	32.48	8.05%	―	17.35%	151.40%
ARGX	68 Neutral	$36.33B	42.41	17.33%	―	78.01%	―
RARE	54 Neutral	$3.50B	―	-214.50%	―	29.01%	23.93%
Sector *	48 Neutral	$6.84B	1.02	-53.11%	2.50%	16.84%	0.92%
VRDN	43 Neutral	$1.18B	―	-45.77%	―	-3.82%	29.10%
IMVT	42 Neutral	$3.12B	―	-74.17%	―	―	-43.10%

Viridian Therapeutics Corporate Events

Viridian Therapeutics Enters New $300M Sale Agreement

On March 3, 2025, Viridian Therapeutics entered into a new Open Market Sale Agreement with Jefferies LLC, allowing the company to offer and sell up to $300 million in common stock to support clinical development and commercialization efforts. This new agreement replaces a prior sale agreement from September 2022, which was terminated after selling $115.2 million in stock, with no costs associated with its early termination.